Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| GemcitabineNCT00209677 | Hokkaido Gastrointestinal Cancer Study GroupPHASE1, PHASE2 | SUSPENDED Unfortunately, other Phase III clinical Study (GEM+S-1 vs GEM vs S-1) have been started in Japan. h | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Interferon gamma-1bNCT00047632 | InterMunePHASE3 | TERMINATED futility | Science15 SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Rosiglitazone and Pegasys/RibavirinNCT00274495 | Beth Israel Medical CenterPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| 5-FUNCT00316745 | Hokkaido Gastrointestinal Cancer Study GroupPHASE3 | SUSPENDED Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| IsovorinNCT00316745 | Hokkaido Gastrointestinal Cancer Study GroupPHASE3 | SUSPENDED Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| L-PlatNCT00316745 | Hokkaido Gastrointestinal Cancer Study GroupPHASE3 | SUSPENDED Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| TS-1NCT00316745 | Hokkaido Gastrointestinal Cancer Study GroupPHASE3 | SUSPENDED Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Campto, TopotesinNCT00316745 | Hokkaido Gastrointestinal Cancer Study GroupPHASE3 | SUSPENDED Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line setting. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-11-01 |
| Chromium PicolinateNCT00332085 | Bastyr UniversityPHASE1 | TERMINATED Issues w/recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-31 |
| Sandostatin LARNCT00175305 | University of British ColumbiaPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-31 |
| TelithromycinNCT00245440 | CPL AssociatesPHASE4 | TERMINATED Sponsor Terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-10-31 |
| AzithromycinNCT00245440 | CPL AssociatesPHASE4 | TERMINATED Sponsor Terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-10-31 |
| MethachoineNCT00550758 | Rambam Health Care CampusNA | TERMINATED the study has recently ended, all information gathred as planed | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-30 |
| L ARGNCT00549575 | Nantes University HospitalPHASE3 | TERMINATED terminated | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-26 |
| acipimoxNCT00449423 | University of AarhusPHASE2 | TERMINATED due to slow recruitment | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-25 |
| Botulinum Toxin A (Botox)NCT00194623 | University of WashingtonPHASE4 | TERMINATED Reorganization of personnel forced termination. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-19 |
| domperidoneNCT00284024 | Hamilton Health Sciences CorporationPHASE2 | TERMINATED Unable to recruit participants | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-15 |
| DDP225NCT00252993 | Dynogen PharmaceuticalsPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-12 |
| NaproxenNCT00410995 | University of OklahomaPHASE4 | TERMINATED Study never initiated. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-11 |
| GliclazideNCT00169624 | Hospices Civils de LyonPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-05 |
| MetforminNCT00169624 | Hospices Civils de LyonPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2007-10-05 |
| SPP301NCT00120328 | Speedel Pharma Ltd.PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2007-10-05 |
| SertralineNCT00232167 | Neurocrine BiosciencesPHASE3 | TERMINATED Please see Detailed Description below for termination reason. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-10-02 |
| IndiplonNCT00232167 | Neurocrine BiosciencesPHASE3 | TERMINATED Please see Detailed Description below for termination reason. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2007-10-02 |
| folic acid 5mg/dayNCT00491907 | University of ZurichPHASE4 | TERMINATED recruitment is finished | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2007-10-02 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |